Abate Kristin, CAO, reported a transaction classified as grant at Karyopharm Therapeutics Inc. involving 933.000000 shares for an estimated $0.00. Reported holdings after the transaction were 10284.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
Chief Accounting Officer
Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics…
Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal…
0 other filings
0 recent txs